Marieke van Son

129 TOXICITY AFTER ULTRAFOCAL SALVAGE HDR-BRACHYTHERAPY Figure 1‑c Figure 1-a,b,c: Stacked barplots displaying number of patients with new-onset toxicity after ultrafocal salvage HDR-BT. At each follow-up time point, toxicity scores were compared with baseline. Any score above baseline was considered new-onset toxicity. Acute/late phase Table 2 shows new-onset toxicity as divided into the acute (≤3 months) and late (>3 months) phase. For the GU domain, grade 2 toxicity increased from 21% (acute phase) to 41% (late phase). Grade 3 GU toxicity only occurred in the late phase. Grade 2 GI toxicity was limited to 2% and 5% in the acute and late phase, respectively. Grade ≥2 ED increased from 22% in the acute phase to 40% in the late phase. Supplementary Table 1 displays acute and late new-onset toxicity for each subdomain. 7